Akagera Medicines
akageramedicines.com
Actively hiring
Education
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
51-200
employees, estimated range
Backers
1
Crocker Ventures
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2018
Founded
Backed byfrom the funds' portfolios and accelerator catalogs
Crocker Ventures Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
About Us Senior Management Team Board of Directors Clinical Advisory Board Technology Pipeline Overview Migaldendranib (MGB) News Resources…
Company Management Team Board of Directors Scientific Advisory Board Clinical Advisory Board Company History Investors Science Biology…
0 Medical Advisory Board. The medical advisory board of Kranus Health consists of highly qualified and renowned physicians with extensive…
Advisory Board Giovanni Mariggi, Director Giovanni is Partner and a member of the co-founding team of Medicxi. He serves on the boards of…
Home Products G5 NTM Use Cases Technology Testimonials News & Blog Latest News Blog Company Company Board of Directors Advisory Board…
Amsel Medical is a medical device company founded in 2011 that boasts some of the industry’s most lauded professionals as part of the…
Overview
AKAGERA Medicines HOME Mission Statement SCIENCE TEAM BOARD OF DIRECTORS AKAGERA MEDICINES, AFRICA SCIENCE ADVISORY BOARD BUSINESS ADVISORY BOARD A Letter About Joe Ritchie & Paul Farmer A Note on our Multi-Culture The Interns Strategy, Partners, Product Pipeline Tuberculosis MECHANISM OF ACTION…
News
Akagera Medicines Reports Positive First-in-Human Data for Single-Ascending-Dose of AKG-100, Advancing a Potentially Transformative Long-Acting Therapeutic for Drug-Resistant Tuberculosis
Akagera Medicines, Inc., a clinical-stage biopharmaceutical company developing lipid-nanoparticle therapeutics and vaccines for infectious diseases that disproportionately affect the majority world, together with the TASK Clinical Research Center in South
Read more
Report
AKAGERA Medicines, Inc. announces the completion of the first cohort in the IV AKG-100 phase 1 study for the treatment of pulmonary tuberculosis.
AKAGERA Medicines, Inc. is a biotech company focused on the discovery and development of novel lipid nanoparticle formulations of antibacterial drugs and mRNA vaccines to treat tuberculosis, avian flu, RSV and other infectious diseases. The company announ
Read more
Report
AKAGERA Medicines, Inc. announces the completion of the first cohort in the IV AKG-100 phase 1 study for the treatment of pulmonary tuberculosis.
Read more
Report
How Rwanda could become vaccine hub for Africa
Rwandan-owned Akagera Medicines and the Coalition for Epidemic Preparedness Innovations (CEPI) entered a new partnership of $1.46 million to improve vaccine delivery and accessibility in Africa. The partnership will see CEPI provide the financial and tech
Read more
Report